Genome Changes in Lung Adenocarcinoma
The Tumor Sequencing Project (locally known as TSP) has been a collaboration of the BCM-HGSC with the Broad Institute of Harvard and MIT, Dana Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University of Michigan Medical Center, and Washington University School of Medicine. The main aim is to speed and facilitate the study of lung cancer under guidelines proposed in the Recommendation for a Human Cancer Genome Project.
TSP examines molecular changes in approximately 1,000 genes with suspected roles in lung adenocarcinomas. Each of the three participating DNA sequencing centers carried out DNA sequencing of a portion of the target genes.
The comprehensive gene list was generated by the Bioinformatics Research Laboratory at BCM-HGSC. The gene lists assigned to each center are also available through the same link.
DNA sequencing has been performed in least 192 independent tumor samples. Identified sequence alterations are being independently confirmed. The resulting data is freely shared between the investigators and rapidly released into the public domain with no claim to specific intellectual property that is based solely on the primary data.
All DNA specimens used in TSP have been anonymized along with their phenotypic data so that an investigator cannot link an individual specimen with a patient identity. All traces from a single sample for a given gene are associated with one another, but the coding and naming that is visible in the public databases will not allow the traces from multiple genes from the same DNA sample to be associated. Investigators interested in the data associations should visit the Cancer Sequencing Project website.